Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan
chemotherapy that in packaged in an inactive substance that is believed to help the
chemotherapy be more stable (meaning that it doesn't lose its effect or need to be
administered quickly after being mixed). It may also have fewer side effects such as problems
with important levels of body electrolytes such as potassium, phosphorous and magnesium; and
cause less kidney and heart damage] than standard formulation melphalan.
The purpose of this study is to determine if the investigators can achieve a certain level of
Captisol Enabled Melphalan that would be best to use in treating Multiple Myeloma and AL